Policy consistency is maintained: Indian Pharmaceutical Alliance
01 February 2022 | Views
Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA)
"This is India's first post vaccination budget and the policy consistency is maintained. The planned increase in capital expenditure is likely to boost economic growth and employment. There is a thrust on macro areas like digital, VC-ecosystem, ease of doing business and supportive measures for R&D and industry-academia collaboration with Pharma included in the Sunrise sectors. The extension time limit for the commencement of business to claim benefits of concessional tax regime for manufacturing companies has been extended by a year to 31 March 2024. This will support the investment in pharma manufacturing. Details are being examined and the implementation will be key going forward."
